A Phase 2 interventional study of Mantle irradiation in Hodgkin's Disease, sponsored by Dana-Farber Cancer Institute. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-11-01.
Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Treatment
The purpose of this study it to evaluate the effectiveness of radiation therapy limited to above the diaphragm in patients with pathological stage IA-IIA Hodgkin's disease.
885 studies on the registry are indexed under Hodgkin Disease; 132 are open to participants now.
This study's enrollment of 100 is above the median of 44 across 726 interventional studies indexed under Hodgkin Disease.
Browse Hodgkin Disease studies →Dana-Farber Cancer Institute is the lead sponsor of 813 studies on the registry; 124 are open to participants now.
Of its 113 completed or terminated interventional studies of FDA-regulated products, 77 (68%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Limited to above the diaphragm
To evaluate the risks and benefits of mantle field irradiation alone in treating Hodgkin disease patients.
Time frame: 5 years
This study is completed, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dana-Farber Cancer Institute